Provided by Tiger Trade Technology Pte. Ltd.

Ascendis Pharma A/S

263.04
+15.136.10%
Pre-market: 263.040.00000.00%08:36 EDT
Volume:1.03M
Turnover:270.01M
Market Cap:17.41B
PE:20.30
High:268.98
Open:247.65
Low:247.65
Close:247.91
52wk High:282.15
52wk Low:186.05
Shares:66.19M
Float Shares:65.54M
Volume Ratio:3.65
T/O Rate:1.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):12.96
EPS(LYR):-4.4176
ROE:118.78%
ROA:9.58%
PB:10.45
PE(LYR):-59.54

Loading ...

How Investors May Respond To Ascendis Pharma (ASND) Achondroplasia Combo Data And YUVIWEL Launch

Simply Wall St.
·
Apr 11

European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading

MT Newswires Live
·
Apr 09

Ascendis Pharma Price Target Maintained With a $273.00/Share by Wedbush

Dow Jones
·
Apr 09

Wedbush Reaffirms Their Buy Rating on Ascendis Pharma (ASND)

TIPRANKS
·
Apr 09

Ascendis Pharma to list ordinary shares directly on Nasdaq from April 20

Reuters
·
Apr 09

Ascendis Pharma announces new data from COACH trial

TIPRANKS
·
Apr 08

Ascendis says COACH trial shows TransCon CNP plus hGH boosts arm span in achondroplasia

Reuters
·
Apr 08

European Equities Traded in the US as American Depositary Receipts Track Lower in Tuesday Trading

MT Newswires Live
·
Apr 07

Ascendis Pharma Gets Orphan Drug Exclusivity for Yuviwel

Dow Jones
·
Apr 07

Ascendis Pharma gets orphan drug exclusivity for Yuviwel, launches in the U.S.

TIPRANKS
·
Apr 07

Analysts Are Bullish on Top Healthcare Stocks: Ascendis Pharma (ASND), Encompass Health (EHC)

TIPRANKS
·
Apr 06

Ascendis Pharma files Form 3 for director Jean-Jacques Bienaime

Reuters
·
Apr 02

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

MT Newswires Live
·
Mar 31

How Investors May Respond To Ascendis Pharma (ASND) Growth‑Disorder Data And New Board Appointment

Simply Wall St.
·
Mar 31

Ascendis Pharma held annual general meeting with 90.16% of shares voted

Reuters
·
Mar 25

European Equities Traded in the US as American Depositary Receipts Climb in Monday Trading

MT Newswires Live
·
Mar 23

Ascendis Pharma A/S EVP and CFO Scott Thomas Smith files initial beneficial ownership statement

Reuters
·
Mar 19

Ascendis Pharma A/S files Form 3 for SVP and PAO Mads Bodenhoff

Reuters
·
Mar 19

Ascendis Pharma Director Lisa Morrison Files Initial Beneficial Ownership Statement

Reuters
·
Mar 19

Ascendis Pharma A/S director Lars Holtug files initial beneficial ownership statement

Reuters
·
Mar 19